75 related articles for article (PubMed ID: 38738384)
21. Febuxostat Use and Risks of Cardiovascular Disease Events, Cardiac Death, and All-cause Mortality: Metaanalysis of Randomized Controlled Trials.
Deng H; Zhang BL; Tong JD; Yang XH; Jin HM
J Rheumatol; 2021 Jul; 48(7):1082-1089. PubMed ID: 32801136
[TBL] [Abstract][Full Text] [Related]
22. Effect of febuxostat on renal function in patients from South China with CKD3 diabetic nephropathy.
Wen H; Yongling Z; Shuying Z; Jiali W; Yanling Z
J Bras Nefrol; 2020; 42(4):393-399. PubMed ID: 32701116
[TBL] [Abstract][Full Text] [Related]
23. Effects of Allopurinol on the Progression of Chronic Kidney Disease.
Badve SV; Pascoe EM; Tiku A; Boudville N; Brown FG; Cass A; Clarke P; Dalbeth N; Day RO; de Zoysa JR; Douglas B; Faull R; Harris DC; Hawley CM; Jones GRD; Kanellis J; Palmer SC; Perkovic V; Rangan GK; Reidlinger D; Robison L; Walker RJ; Walters G; Johnson DW;
N Engl J Med; 2020 Jun; 382(26):2504-2513. PubMed ID: 32579811
[TBL] [Abstract][Full Text] [Related]
24. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.
Doria A; Galecki AT; Spino C; Pop-Busui R; Cherney DZ; Lingvay I; Parsa A; Rossing P; Sigal RJ; Afkarian M; Aronson R; Caramori ML; Crandall JP; de Boer IH; Elliott TG; Goldfine AB; Haw JS; Hirsch IB; Karger AB; Maahs DM; McGill JB; Molitch ME; Perkins BA; Polsky S; Pragnell M; Robiner WN; Rosas SE; Senior P; Tuttle KR; Umpierrez GE; Wallia A; Weinstock RS; Wu C; Mauer M;
N Engl J Med; 2020 Jun; 382(26):2493-2503. PubMed ID: 32579810
[TBL] [Abstract][Full Text] [Related]
25. Febuxostat as a renoprotective agent for treatment of hyperuricaemia: a meta-analysis of randomised controlled trials.
Chewcharat A; Chen Y; Thongprayoon C; Harrison AM; Mao MA; Cheungpasitporn W
Intern Med J; 2021 May; 51(5):752-762. PubMed ID: 32149437
[TBL] [Abstract][Full Text] [Related]
26. Xanthine oxidase inhibitor ameliorates postischemic renal injury in mice by promoting resynthesis of adenine nucleotides.
Fujii K; Kubo A; Miyashita K; Sato M; Hagiwara A; Inoue H; Ryuzaki M; Tamaki M; Hishiki T; Hayakawa N; Kabe Y; Itoh H; Suematsu M
JCI Insight; 2019 Nov; 4(22):. PubMed ID: 31723053
[TBL] [Abstract][Full Text] [Related]
27. Febuxostat, a novel inhibitor of xanthine oxidase, reduces ER stress through upregulation of SIRT1-AMPK-HO-1/thioredoxin expression.
Kim H; Baek CH; Chang JW; Yang WS; Lee SK
Clin Exp Nephrol; 2020 Mar; 24(3):205-215. PubMed ID: 31677062
[TBL] [Abstract][Full Text] [Related]
28. Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice.
Mizuno Y; Yamamotoya T; Nakatsu Y; Ueda K; Matsunaga Y; Inoue MK; Sakoda H; Fujishiro M; Ono H; Kikuchi T; Takahashi M; Morii K; Sasaki K; Masaki T; Asano T; Kushiyama A
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546603
[TBL] [Abstract][Full Text] [Related]
29. Effect of febuxostat on oxidative stress in hemodialysis patients with endothelial dysfunction: a randomized, placebo-controlled, double-blinded study.
Alshahawey M; Shaheen SM; Elsaid T; Sabri NA
Int Urol Nephrol; 2019 Sep; 51(9):1649-1657. PubMed ID: 31368057
[TBL] [Abstract][Full Text] [Related]
30. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.
Kojima S; Matsui K; Hiramitsu S; Hisatome I; Waki M; Uchiyama K; Yokota N; Tokutake E; Wakasa Y; Jinnouchi H; Kakuda H; Hayashi T; Kawai N; Mori H; Sugawara M; Ohya Y; Kimura K; Saito Y; Ogawa H
Eur Heart J; 2019 Jun; 40(22):1778-1786. PubMed ID: 30844048
[TBL] [Abstract][Full Text] [Related]
31. Febuxostat inhibits TGF‑β1‑induced epithelial‑mesenchymal transition via downregulation of USAG‑1 expression in Madin‑Darby canine kidney cells in vitro.
Lu L; Zhu J; Zhang Y; Wang Y; Zhang S; Xia A
Mol Med Rep; 2019 Mar; 19(3):1694-1704. PubMed ID: 30628645
[TBL] [Abstract][Full Text] [Related]
32. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
[TBL] [Abstract][Full Text] [Related]
33. Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: A 6-months open-label, randomized controlled trial.
Mukri MNA; Kong WY; Mustafar R; Shaharir SS; Shah SA; Abdul Gafor AH; Mohd R; Abdul Cader R; Kamaruzaman L
EXCLI J; 2018; 17():563-575. PubMed ID: 30108461
[No Abstract] [Full Text] [Related]
34. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
Gunawardhana L; Becker MA; Whelton A; Hunt B; Castillo M; Saag K
Arthritis Res Ther; 2018 May; 20(1):99. PubMed ID: 29848361
[TBL] [Abstract][Full Text] [Related]
35. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis.
Liu X; Zhai T; Ma R; Luo C; Wang H; Liu L
Ren Fail; 2018 Nov; 40(1):289-297. PubMed ID: 29619870
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB; Saag KG; Becker MA; Borer JS; Gorelick PB; Whelton A; Hunt B; Castillo M; Gunawardhana L;
N Engl J Med; 2018 Mar; 378(13):1200-1210. PubMed ID: 29527974
[TBL] [Abstract][Full Text] [Related]
37. Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis.
Pisano A; Cernaro V; Gembillo G; D'Arrigo G; Buemi M; Bolignano D
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29088122
[TBL] [Abstract][Full Text] [Related]
38. Effect of Febuxostat on the Endothelial Dysfunction in Hemodialysis Patients: A Randomized, Placebo-Controlled, Double-Blinded Study.
Alshahawey M; Shahin SM; Elsaid TW; Sabri NA
Am J Nephrol; 2017; 45(5):452-459. PubMed ID: 28463849
[TBL] [Abstract][Full Text] [Related]
39. A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy.
Beddhu S; Filipowicz R; Wang B; Wei G; Chen X; Roy AC; DuVall SL; Farrukh H; Habib AN; Bjordahl T; Simmons DL; Munger M; Stoddard G; Kohan DE; Greene T; Huang Y
Can J Kidney Health Dis; 2016; 3():2054358116675343. PubMed ID: 28270924
[TBL] [Abstract][Full Text] [Related]
40. Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes.
Komers R; Xu B; Schneider J; Oyama TT
Br J Pharmacol; 2016 Sep; 173(17):2573-88. PubMed ID: 27238746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
